These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 3265148

  • 1. Preclinical trials using an immunoconjugate of T101 and methotrexate in an athymic mouse/human T-cell tumor model.
    Shawler DL, Johnson DE, Sweet MD, Myers LJ, Tudor SD, Beidler DE, Koziol JA, Dillman RO.
    J Biol Response Mod; 1988 Dec; 7(6):608-18. PubMed ID: 3265148
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of human T-cell tumor growth by T101-ricin A-chain in an athymic mouse model.
    Leonard JE, Johnson DE, Shawler DL, Dillman RO.
    Cancer Res; 1988 Sep 01; 48(17):4862-7. PubMed ID: 3261627
    [Abstract] [Full Text] [Related]

  • 3. Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates.
    Dillman RO, Johnson DE, Ogden J, Beidler D.
    Mol Biother; 1989 Sep 01; 1(5):250-5. PubMed ID: 2515870
    [Abstract] [Full Text] [Related]

  • 4. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model.
    Weil-Hillman G, Runge W, Jansen FK, Vallera DA.
    Cancer Res; 1985 Mar 01; 45(3):1328-36. PubMed ID: 3971376
    [Abstract] [Full Text] [Related]

  • 5. Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug.
    Dillman RO, Johnson DE, Shawler DL, Koziol JA.
    Cancer Res; 1988 Nov 01; 48(21):6097-102. PubMed ID: 3262420
    [Abstract] [Full Text] [Related]

  • 6. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
    Kawata A, Yoshida M, Okazaki M, Yokota S, Barcos M, Seon BK.
    Cancer Res; 1994 May 15; 54(10):2688-94. PubMed ID: 8168098
    [Abstract] [Full Text] [Related]

  • 7. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
    Scott CF, Goldmacher VS, Lambert JM, Jackson JV, McIntyre GD.
    J Natl Cancer Inst; 1987 Nov 15; 79(5):1163-72. PubMed ID: 3500356
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Athymic mouse model of a human T-cell tumor.
    Dillman RO, Johnson DE, Shawler DL, Halpern SE, Leonard JE, Hagan PL.
    Cancer Res; 1985 Nov 15; 45(11 Pt 2):5632-6. PubMed ID: 3902212
    [Abstract] [Full Text] [Related]

  • 11. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA, Halloran PM, Ferris CA, Levine BA, Bourret LA, Goldmacher VS, Blättler WA.
    Cancer Res; 1993 Mar 15; 53(6):1360-7. PubMed ID: 7680284
    [Abstract] [Full Text] [Related]

  • 12. Preclinical trials with combinations and conjugates of T101 monoclonal antibody and doxorubicin.
    Dillman RO, Shawler DL, Johnson DE, Meyer DL, Koziol JA, Frincke JM.
    Cancer Res; 1986 Oct 15; 46(10):4886-91. PubMed ID: 2428468
    [Abstract] [Full Text] [Related]

  • 13. Cytotoxic effects of anti-CD5 radioimmunotoxins on human tumors in vitro and in a nude mouse model.
    Manske JM, Buchsbaum DJ, Hanna DE, Vallera DA.
    Cancer Res; 1988 Dec 15; 48(24 Pt 1):7107-14. PubMed ID: 2461252
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of methotrexate-monoclonal anti-prostatic acid phosphatase antibody conjugate on human prostate tumor.
    Deguchi T, Chu TM, Leong SS, Horoszewicz JS, Lee CL.
    Cancer Res; 1986 Aug 15; 46(8):3751-5. PubMed ID: 3731053
    [Abstract] [Full Text] [Related]

  • 17. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB.
    Pollack VA, Alvarez E, Tse KF, Torgov MY, Xie S, Shenoy SG, MacDougall JR, Arrol S, Zhong H, Gerwien RW, Hahne WF, Senter PD, Jeffers ME, Lichenstein HS, LaRochelle WJ.
    Cancer Chemother Pharmacol; 2007 Aug 15; 60(3):423-35. PubMed ID: 17541593
    [Abstract] [Full Text] [Related]

  • 18. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B, Siegel SE, Kaiser HE.
    Anticancer Res; 1996 Aug 15; 16(2):661-74. PubMed ID: 8687112
    [Abstract] [Full Text] [Related]

  • 19. Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon.
    Greiner JW, Ullmann CD, Nieroda C, Qi CF, Eggensperger D, Shimada S, Steinberg SM, Schlom J.
    Cancer Res; 1993 Feb 01; 53(3):600-8. PubMed ID: 8425194
    [Abstract] [Full Text] [Related]

  • 20. Antitumor activity of the monoclonal antibody-Vinca alkaloid immunoconjugate LY203725 (KS1/4-4-desacetylvinblastine-3-carboxhydrazide) in a nude mouse model of human ovarian cancer.
    Apelgren LD, Zimmerman DL, Briggs SL, Bumol TF.
    Cancer Res; 1990 Jun 15; 50(12):3540-4. PubMed ID: 2340502
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.